Diasolution is the first drug for peritoneal dialysis, that was developed and produced in Russia. Previously, such drugs were only supplied by foreign manufacturers.
In the first quarter of 2024, the full line of Diasolution solutions in volumes of 2000, 2500 and 5000 ml with glucose concentrations of 1.5%, 2.3% and 4.25% required for continuous outpatient and automated peritoneal dialysis procedures will be available to medical institutions in Moscow, St. Petersburg, Northwestern Federal District, Central Federal District, Southern Federal District, Volga Federal District, Siberia and Russia’s Far East.
Today, more than 50,000 people in Russia are treated with dialysis methods of renal replacement therapy, and the number of such patients is steadily growing. Over the past 10 years, Russia has been among the TOP 15 countries in terms of the growth rate of patients provided with modern methods of treating end-stage chronic kidney disease. Today, about 2,000 patients are treated with peritoneal dialysis method in the Russian Federation. This method, unlike hemodialysis, is a variant of at-home dialysis therapy, which allows patients to receive treatment on their own every day, at home. Thus, it is of vital importance for them to have the main components of this therapy - special dialysis solutions.
“During last few years, while discussing the ways of developing renal replacement therapy in Russia, the emphasis has been made of the increase of number of patients with a transplanted kidney and patients who receive peritoneal dialysis, which has several clinical advantages and is the only available at-home dialysis treatment method in our country. These methods allow to improve the end-stage chronic kidney disease patients’ life quality and let them be independent from specialized clinics. The development of import substitution of solutions for peritoneal dialysis is an important step in establishing sustainability of drug supply for Russian patients and ensuring access to the most modern treatment methods,” explained Anton Andrusev, medical director of Novadial.
“More than 90 % of dialysis procedures require imported components. Today it is essential to develop internal, domestic manufacture of medical products and equipment for dialysis due to the complicated geopolitical situation and the cessation of supplies to the Russian Federation by a number of Western manufacturers. The launch of the manufacture and supply of the first domestic solutions line for peritoneal dialysis Diasolution is the most significant step in dialysis import substitution. The Novadial company strategic mission is to provide the full scope of high quality products and services required for all types of dialysis treatment that are produced by domestic or friendly nations’ companies for affordable prices and with controlled supply schedules. The company is preparing to launch about 100 new types of high-quality dialysis consumables on the market, which are compatible with dialysis systems from global manufacturers,” said Alexey Kataev, General Director of Novadial.
“East-Pharm company has been present in the pharmaceutical market for more than 20 years and has proven itself to be a reliable infusion solutions manufacturer. We launched a new project on the production of solutions for peritoneal dialysis.. The relevance of the project implementation is proven by the demand for drug products in Russia, as all the substitute medications are imported nowadays. Thanks to the launched production, patients will be able to be less dependent on foreign manufacturers,” said Yury Skachko, Chief Executive Officer of EAST-PHARM.